Interstitial Lung Disease is an umbrella term for a large and diverse group of disorders that primarily affect the lung interstitium and often adjacent alveolar epithelium, airways and pulmonary vessels. The interstitium is the connective-tissue framework between alveolar spaces and contains structural components, blood vessels, immune cells and extracellular matrix.
In practice, many disorders classified as Interstitial Lung Disease extend beyond the microscopic interstitium, so the term describes a broad group of diffuse parenchymal lung diseases rather than a narrowly confined anatomical lesion. Some forms are predominantly inflammatory, some predominantly fibrotic and many contain varying combinations of inflammation and scarring. Causes include autoimmune disease, occupational and environmental exposure, medication toxicity, infection, inherited disorders and unknown mechanisms. Common manifestations include exertional breathlessness, persistent cough, reduced exercise tolerance and abnormal oxygenation. The category is clinically important because individual diseases within it can have very different treatments and prognoses, making accurate classification more important than simply recognising that an interstitial abnormality exists.
Interstitial Lung Disease includes numerous recognised disease patterns and causal groups. Connective-tissue diseases can produce lung inflammation and fibrosis through immune-mediated injury. Hypersensitivity pneumonitis can arise from repeated inhalation of sensitising organic or chemical antigens and may have inflammatory, fibrotic or mixed manifestations. Occupational and environmental disorders can follow exposure to mineral dusts, fibres, metals, moulds or other airborne substances. Certain medicines and radiation can cause diffuse parenchymal injury.
Granulomatous disorders, smoking-related interstitial disorders and rare inherited conditions add further diversity. Some patients have interstitial abnormalities associated with another systemic disease without initially having obvious extrapulmonary manifestations. Others have no identifiable cause despite extensive investigation and are classified within idiopathic categories according to established clinical and radiological patterns. The causal distinction is essential because removing an antigen or occupational exposure can be fundamental in one disease, immunosuppression may be central in another, and antifibrotic therapy may be appropriate for selected progressive fibrotic phenotypes.
The pathobiology of Interstitial Lung Disease varies but commonly involves injury to alveolar epithelial cells, abnormal immune activation, fibroblast proliferation and changes in extracellular matrix. In inflammatory forms, immune cells release mediators that recruit additional inflammatory cells and alter tissue permeability. If the injurious stimulus persists, repair can become maladaptive and fibroblasts may produce excessive collagen, leading to fibrosis. Fibrotic remodelling thickens the alveolar-capillary barrier and reduces compliance.
Gas diffusion becomes less efficient, particularly during exercise, and destruction or remodelling of pulmonary capillary beds can contribute to pulmonary hypertension. In some diseases, granulomas form as organised immune structures in response to persistent antigenic stimulation. In others, epithelial dysfunction and abnormal wound repair dominate rather than conventional inflammation. This biological diversity explains why a generic treatment approach is inappropriate. A disease that appears radiologically "interstitial" can therefore arise from fundamentally different mechanisms, ranging from reversible inflammation to progressive scar formation, and treatment depends on identifying which mechanism is most likely operating.
Assessment of Interstitial Lung Disease requires integration of clinical history, high-resolution computed tomography, pulmonary function tests, exposure assessment, blood tests and often multidisciplinary interpretation. A detailed exposure history is particularly important because patients may not recognise that hobbies, household materials, occupational tasks or environmental conditions are relevant. Autoimmune symptoms such as joint pain, Raynaud-type vascular symptoms, skin changes or muscle weakness may provide clues to connective-tissue disease even when lung symptoms dominate.
High-resolution computed tomography can identify patterns of ground-glass opacity, reticulation, nodules, consolidation, architectural distortion, traction bronchiectasis or honeycombing. Pulmonary function tests commonly show restriction and reduced diffusing capacity, although obstructive or mixed physiology can occur. Exercise testing can reveal exertional desaturation and quantify functional limitation. Bronchoscopy, lavage or biopsy may be considered when non-invasive information does not provide sufficient diagnostic confidence and when the result is likely to alter treatment.
Treatment is determined by the specific Interstitial Lung Disease and its activity, severity and trajectory. Avoiding causative exposures is essential in exposure-related disease and may prevent further injury. Inflammatory autoimmune disorders may respond to immunosuppressive or immunomodulatory therapies, while selected progressive fibrotic diseases can be treated with antifibrotic medicines designed to slow loss of lung function. Corticosteroids are useful in some inflammatory disorders but are not a universal treatment for fibrotic disease and can produce substantial adverse effects.
Supportive treatment includes pulmonary rehabilitation, oxygen therapy when indicated, vaccination, nutritional support and management of pulmonary hypertension or other complications. Smoking cessation is important because smoke can worsen several forms of parenchymal lung disease. Drug treatment must be individualised because immunosuppression can increase infection risk and may be inappropriate in certain fibrotic disorders. Monitoring is usually longitudinal, with serial lung-function measurements, symptoms, exercise capacity and sometimes imaging used to determine whether disease is stable, improving or progressing.
The distinction between stable, inflammatory and progressive fibrotic Interstitial Lung Disease has major clinical significance. Some inflammatory disorders can improve substantially after the underlying trigger is removed or immune activity is controlled. Other diseases may remain stable for long periods without intensive treatment. Progressive fibrotic phenotypes, however, can show continuing decline in lung function despite different underlying diagnoses. Acute deterioration may result from infection, pulmonary embolism, heart failure, drug toxicity or acute exacerbation of the underlying lung disease.
Pulmonary hypertension and chronic hypoxaemia can add substantial physiological burden. Advanced disease may lead to respiratory failure and consideration of transplantation. Prognosis therefore cannot be inferred from the umbrella term alone. A diagnosis of Interstitial Lung Disease identifies a broad clinical territory, not a single predictable disease course. Modern classification increasingly emphasises disease behaviour and biological phenotype in addition to traditional diagnostic labels, particularly when deciding whether antifibrotic or immunomodulatory treatment is appropriate.
Interstitial Lung Disease has historically been difficult to classify because different conditions can produce overlapping clinical, radiological and pathological findings. Modern multidisciplinary diagnosis uses the combined expertise of respiratory physicians, radiologists, pathologists and other specialists rather than treating any single test as definitive. High-resolution computed tomography has greatly reduced the need for invasive biopsy in cases with characteristic patterns, while molecular and genetic research continues to reveal biological differences within apparently similar radiological categories.
The terminology can be confusing because "interstitial" does not mean that only the microscopic interstitial tissue is affected. Alveoli, small airways, vessels and pleura can also become involved. Similarly, "diffuse parenchymal lung disease" is sometimes used as a broader descriptive concept. These distinctions matter when interpreting medical literature, because terms that appear synonymous may have different diagnostic scopes.
A common misconception is that Interstitial Lung Disease is synonymous with Pulmonary Fibrosis. Pulmonary Fibrosis describes fibrotic scarring, whereas Interstitial Lung Disease includes both fibrotic and predominantly inflammatory disorders, as well as diseases with mixed patterns. Another misconception is that all interstitial diseases are rare and inevitably fatal. The category contains many uncommon conditions, but their severity and trajectories vary widely, and some respond well to treatment or exposure avoidance.
Interstitial Lung Disease also differs fundamentally from airway disorders such as asthma because the dominant pathology is generally within the lung parenchyma rather than reversible airway narrowing. The category is important because it forces clinicians to investigate cause and biological behaviour rather than relying on a broad label. Its complexity reflects the fact that the lung can respond to many different injuries through a limited set of recurring patterns, while the initiating causes and appropriate treatments remain highly diverse.
